Omega‐3 vs placebo: Serious adverse events: major bleeding
- Population
- dialysis vascular access outcomes in AVG patients with ESKD
- Intervention
- Omega‐3
- Comparison
- placebo
- Outcome
- Serious adverse events: major bleeding
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: major bleeding compared with placebo (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Omega‐3 fatty acids vs Placebo Serious adverse events: major bleeding · dialysis vascular access outcomes in AVG patients with ESKD It is very uncertain whether omega‐3 fatty acids changes serious adverse events: major bleeding compared with placebo (very low certainty). Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease (2018) · Cochrane Headline outcomes only | RD 0.08 | 3 studies · 65 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Omega‐3 vs placebo · Dialysis vascular access outcomes in AVF patients with ESKD · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.